An Overview of Amyotrophic Lateral Sclerosis

episode

JAMA Clinical Reviews not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

#502 – Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung 3h 43m · 17 Sep 2026 · Lex Fridman Podcast

Your partner wants profit. You want freedom. Now what? 22 min · 16 Sep 2026 · The Optometry Success Podcast

Board of County Supervisors Meeting - Work Session - Sep 15, 2026 3h 17m · 15 Sep 2026 · Prince William County Board of Supervisors

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

Sept. 15, 2026 Board of Supervisors Meeting 8h 46m · 15 Sep 2026 · Fairfax County Board of Supervisors

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

Report any issue

Source

Recorded11 May 2026

Publisherjamaclinicalreviews.libsyn.com ↗

Handlerec:18346163

Show notes

Amyotrophic lateral sclerosis (ALS), which affects about 25 000 individuals in the US, causes progressive weakness but has varied presentations. Several FDA-approved medications are now available for ALS. Author John Ravits, MD, of UC San Diego School of Medicine joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss current evidence regarding diagnosis and treatment of ALS. Related Content: Amyotrophic Lateral Sclerosis Pridopidine in Amyotrophic Lateral Sclerosis What Is Amyotrophic Lateral Sclerosis? CNM-Au8 in Amyotrophic Lateral Sclerosis Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis Traumatic Brain Injury and Risk of Amyotrophic Lateral Sclerosis

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in